Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon

Kyle L O’Donnell, Andrea Marzi Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USACorrespondence: Andrea Marzi Email marzia@niaid.nih.govAbstract: Ebola virus disease (EVD) remains...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	O'Donnell KL, Marzi A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	ebolavirus filovirus immune response monoclonal antibodies interferon Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/be1614737e824619a0a6e0158cf18527
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be1614737e824619a0a6e0158cf18527
record_format	dspace
spelling	oai:doaj.org-article:be1614737e824619a0a6e0158cf185272021-12-02T11:39:16ZImmunotherapeutics for Ebola Virus Disease: Hope on the Horizon1177-5491https://doaj.org/article/be1614737e824619a0a6e0158cf185272021-03-01T00:00:00Zhttps://www.dovepress.com/immunotherapeutics-for-ebola-virus-disease-hope-on-the-horizon-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Kyle L O’Donnell, Andrea Marzi Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USACorrespondence: Andrea Marzi Email marzia@niaid.nih.govAbstract: Ebola virus disease (EVD) remains among the biggest public health threats in Africa, even though recently a vaccine was approved for human use. However, in outbreak situations treatment strategies are needed in combination with vaccination campaigns to impact and stop the spread of the disease. Here, we discuss the development of the immunotherapeutics against EDV both targeting the virus itself and bolstering the immunological environment of the host at both the pre-clinical and clinical level. The early development of antibody therapy in preclinical settings and the early pitfalls in the implementation of this therapeutic strategy are discussed. We also consider the advancement of the production, modulation, and specificity of the antibody treatment that garnered increased success in preclinical studies to the point that it was warranted to test them in a clinical setting. Initial clinical trials in an outbreak scenario proved difficult to definitively confirm the efficacy of the implemented treatment. Upon further modification and with the experiences from the challenging outbreak conditions in mind, the PALM clinical trial demonstrated efficacy of an antibody cocktail which recently received approval for human use.Keywords: Ebolaviruses, filovirus, immune response, monoclonal antibodies, interferonO'Donnell KLMarzi ADove Medical Pressarticleebolavirusfilovirusimmune responsemonoclonal antibodiesinterferonMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 79-86 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ebolavirus filovirus immune response monoclonal antibodies interferon Medicine (General) R5-920
spellingShingle	ebolavirus filovirus immune response monoclonal antibodies interferon Medicine (General) R5-920 O'Donnell KL Marzi A Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon
description	Kyle L O’Donnell, Andrea Marzi Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USACorrespondence: Andrea Marzi Email marzia@niaid.nih.govAbstract: Ebola virus disease (EVD) remains among the biggest public health threats in Africa, even though recently a vaccine was approved for human use. However, in outbreak situations treatment strategies are needed in combination with vaccination campaigns to impact and stop the spread of the disease. Here, we discuss the development of the immunotherapeutics against EDV both targeting the virus itself and bolstering the immunological environment of the host at both the pre-clinical and clinical level. The early development of antibody therapy in preclinical settings and the early pitfalls in the implementation of this therapeutic strategy are discussed. We also consider the advancement of the production, modulation, and specificity of the antibody treatment that garnered increased success in preclinical studies to the point that it was warranted to test them in a clinical setting. Initial clinical trials in an outbreak scenario proved difficult to definitively confirm the efficacy of the implemented treatment. Upon further modification and with the experiences from the challenging outbreak conditions in mind, the PALM clinical trial demonstrated efficacy of an antibody cocktail which recently received approval for human use.Keywords: Ebolaviruses, filovirus, immune response, monoclonal antibodies, interferon
format	article
author	O'Donnell KL Marzi A
author_facet	O'Donnell KL Marzi A
author_sort	O'Donnell KL
title	Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon
title_short	Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon
title_full	Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon
title_fullStr	Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon
title_full_unstemmed	Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon
title_sort	immunotherapeutics for ebola virus disease: hope on the horizon
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/be1614737e824619a0a6e0158cf18527
work_keys_str_mv	AT odonnellkl immunotherapeuticsforebolavirusdiseasehopeonthehorizon AT marzia immunotherapeuticsforebolavirusdiseasehopeonthehorizon
_version_	1718395785222029312

Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon

Ejemplares similares